콘텐츠로 건너뛰기
Merck
  • Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.

Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.

Oncogene (2021-09-25)
Timofey Lebedev, Elmira Vagapova, Pavel Spirin, Petr Rubtsov, Olga Astashkova, Alesya Mikheeva, Maxim Sorokin, Uliana Vladimirova, Maria Suntsova, Dmitry Konovalov, Alexander Roumiantsev, Carol Stocking, Anton Buzdin, Vladimir Prassolov
초록

Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the cancer cells' ability to adapt to these drugs through the employment of alternative signaling pathways. Based on the expression of 48 growth factor-related genes in 1189 NB tumors, we have developed a model for NB patient survival prediction. This model discriminates between stage 4 NB tumors with favorable outcomes (>80% overall survival) and very poor outcomes (<10%) independently from MYCN-amplification status. Using signaling pathway analysis and gene set enrichment methods in 60 NB patients with known therapy response, we identified signaling pathways, including EPO, NGF, and HGF, upregulated in patients with no or partial response. In a therapeutic setting, we showed that among six selected growth factors, EPO, and NGF showed the most pronounced protective effects in vitro against several promising anti-NB multikinase inhibitors: imatinib, dasatinib, crizotinib, cabozantinib, and axitinib. Mechanistically kinase inhibitors potentiated NB cells to stronger ERK activation by EPO and NGF. The protective action of these growth factors strongly correlated with ERK activation and was ERK-dependent. ERK inhibitors combined with anticancer drugs, especially with dasatinib, showed a synergistic effect on NB cell death. Consideration of growth factor signaling activity benefits NB outcome prediction and tailoring therapy regimens to treat NB.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Monoclonal Anti-Rabbit Immunoglobulins–FITC antibody produced in mouse, clone RG-16, purified immunoglobulin, buffered aqueous solution